CN108853042A - A kind of Mirtazapine freeze-drying oral disintegrating tablet and its preparation method and application - Google Patents
A kind of Mirtazapine freeze-drying oral disintegrating tablet and its preparation method and application Download PDFInfo
- Publication number
- CN108853042A CN108853042A CN201811101902.9A CN201811101902A CN108853042A CN 108853042 A CN108853042 A CN 108853042A CN 201811101902 A CN201811101902 A CN 201811101902A CN 108853042 A CN108853042 A CN 108853042A
- Authority
- CN
- China
- Prior art keywords
- mirtazapine
- parts
- oral disintegrating
- disintegrating tablet
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Abstract
The invention discloses a kind of Mirtazapine freeze-drying oral disintegrating tablets and preparation method thereof.Mirtazapine freeze-drying oral disintegrating tablet of the invention includes 15 parts of Mirtazapines, 5~10 parts of skeletal support agent, 10~20 parts of freeze drying protectants, 39~45 parts of solubilizer and 1.5~2 parts of corrigents; and the partial size of Mirtazapine is less than or equal to 50um; it is prepared using freeze-drying, and gives Mirtazapine freeze-drying oral disintegrating tablet of the present invention and preparing the application in antidepressants.
Description
Technical field
The present invention relates to a kind of Mirtazapine freeze-drying oral disintegrating tablets and its preparation method and application, belong to oral preparation field.
Background technique
Mirtazapine tablets are a kind of novel antidepressants, and active constituent Mirtazapine passes through antagonism maincenter itself and allogeneic
Adrenaline alpha-2 receptor increases the release of norepinephrine and serotonin (5-HT) and generates antidepressant effect.And its
The effect for discharging 5-HT is that then have blocking effect to 5-HT2 and 5-HT3 receptor, to adrenal gland by special 5-HT1 receptor
Plain 1 receptor of α and M- receptor affinity are very low, therefore do not have postural hypotension and anticholinergic adverse reaction.Although with histamine
Receptor has great affinity, but will not clinically cause too strong sedation.
After oral mirtazapine tablets, active constituent Mirtazapine is absorbed (bioavilability is about 50%) quickly, and about two is small
When after plasma concentration peak, about 85% in conjunction with plasma protein, and mean half-life is 20-40 hours, and accidental to be up to 65 small
When, also accidental shorter half-life period in young man.The size for removing half-life period, which is just being suitable for that mode will be taken, is set to daily one
It is secondary.Blood concentration reaches stable state after medication three to four days, hereafter will build up phenomenon without internal.In the dosage model recommended
In enclosing, the pharmacokinetics form of Mirtazapine be it is linear, Mirtazapine be metabolized mostly and pass through in several days after the tablet has been ingested urine with
Excrement excretes.Its main biochemical mode is demethylation and oxidation reaction, is followed by association reaction.Metabolite after piptonychia
Still has pharmacological activity as former compound.
The mirtazapine tablets for having 15mg that Mirtazapine is listed in the country of China, have no oral disintegrating tablet, and there are no freeze-dried type oral disintegrating tablets.It is logical
Cross the In Vitro Dissolution behavior of the comparison embodiment of the present invention 1 with the 15mg mirtazapine tablets listed in China, the embodiment of the present invention 1
Dissolution rate be significantly faster than the dissolution rates of mirtazapine tablets, In Vitro Dissolution behavior can reflect out intracorporal infiltration rate, by
This can be seen that the present invention can effectively improve the bioavilability of Mirtazapine, and be the oral disintegrating tablet of freeze-dried type in view of the present invention,
It is easy to carry to take without using water, patient is more conducive to take.
Summary of the invention
It is an object of the present invention to provide a kind of Mirtazapine freeze-drying oral disintegrating tablets and its preparation method and application.
In order to achieve the above object, the present invention provides a kind of Mirtazapine freeze-drying oral disintegrating tablet, in parts by weight, including 15 parts of rice nitrogen
Flat, 5~10 parts of skeletal support agent, 10~20 parts of freeze drying protectants, 39~45 parts of solubilizer and 1.5~2 parts of corrigents；And rice nitrogen
Flat partial size is less than or equal to 50um.
Preferably, in parts by weight, including 15 parts of Mirtazapines, 6 parts of skeletal support agent, 15 parts of freeze drying protectants, 40 parts increasing
Solvent and 1.8 parts of corrigents.
Preferably, the skeletal support agent is selected from gelatin, hypromellose, xylitol, trehalose, pulullan polysaccharide
One of them or combinations thereof；It is furthermore preferred that the skeletal support agent is hypromellose E5.Skeletal support agent is in order to anti-
Only tablet collapses after dehydration is lyophilized, for keeping pill shapes.
Preferably, the freeze drying protectant is mannitol or pulullan polysaccharide；It is furthermore preferred that the freeze drying protectant is sweet
Reveal alcohol.
Preferably, the solubilizer is selected from glacial acetic acid, citric acid or tartaric acid；It is furthermore preferred that the solubilizer is lemon
Acid.
Preferably, the corrigent is selected from one of Sucralose, Steviosin, essence or combinations thereof；It is furthermore preferred that institute
Stating corrigent is Sucralose and morello essence.
The present invention also provides the preparation methods of above-mentioned Mirtazapine freeze-drying oral disintegrating tablet, include the following steps：
(1) solubilizer of claim 1 parts by weight and Mirtazapine are added in suitable quantity of water and are sufficiently dissolved, add skeleton branch
It is sufficiently uniformly dissolved after support agent, freeze drying protectant and corrigent, is settled to 300ml with water；
(2) medical fluid made from aspiration step (1) is added into tablet die；
(3) mold for being loaded with medical fluid that step (2) obtains is frozen into type in -75~-120 DEG C of environment middling speed；
(4) the quick-frozen molding solid medical fluid for obtaining step (3) is put into freeze dryer, is kept for 30 minutes at -40 DEG C, is taken out
Vacuum to vacuum degree is 10~20Pa, is kept for 120 minutes, is warming up to -25~-15 DEG C and is kept for 120 minutes, is warming up to -15~0 DEG C
It is kept for 120 minutes, is warming up to 5~10 DEG C and is kept for 120 minutes, be warming up to 20~25 DEG C and kept for 120 minutes, be warming up to 30~35 DEG C
It is kept for 180 minutes；
(5) outlet, overlay film, punching, printing lot number.
The present invention also provides above-mentioned Mirtazapine freeze-drying oral disintegrating tablets to prepare the application in antidepressants.
Detailed description of the invention
Fig. 1 is the In Vitro Dissolution curve of Mirtazapine commercially available product and embodiment 1 in 0.1M hydrochloric acid solution；
Fig. 2 is the In Vitro Dissolution curve of Mirtazapine commercially available product and embodiment 1 in pH4.0 acetate buffer；
Fig. 3 is the In Vitro Dissolution curve of Mirtazapine commercially available product and embodiment 1 in pH4.5 phosphate buffer；
Fig. 4 is the In Vitro Dissolution curve of Mirtazapine commercially available product and embodiment 1 in pH6.8 phosphate buffer；
Fig. 5 is the Drug-time curve figure before the meal that the pharmacokinetic indicator of embodiment 1 (T) and Remeron (R) is tested；
Fig. 6 is the postprandial Drug-time curve figure that the pharmacokinetic indicator of embodiment 1 (T) and Remeron (R) is tested.
Specific embodiment
The invention will now be further described with reference to specific embodiments, the advantages and features of the present invention will be with description and
It is apparent.But examples are merely exemplary for these, and it is not intended to limit the scope of the present invention in any way.Those skilled in the art
Member it should be understood that without departing from the spirit and scope of the invention can details to technical solution of the present invention and form into
Row modifications or substitutions, but these modifications and replacement are fallen within the protection scope of the present invention.
Solubilizer is selected by dissolubility
Due to Mirtazapine raw material slightly soluble in water, and it is few to prepare quantity of solvent used in freeze-drying oral disintegrating tablet, its can not be made complete
Fully dissolved, it is therefore necessary to certain solubilizer be added.
This experimental example investigates the dissolubility of bulk pharmaceutical chemicals, and research obtains Mirtazapine, and dissolubility is most under slant acidity environment
It is good.Since solubilizer action principle is to increase the solubility of drug in water, is investigated and closed according to the solubility of Mirtazapine
Suitable solubilizer, show that good solubilizer has glacial acetic acid, citric acid, tartaric acid etc..And since citric acid makes in food, medicine
With the most extensively, while citric acid also has effects that flavoring, therefore present invention preferably uses citric acids.
Further the dosage of citric acid is investigated, experimental result is as shown in table 1.
1 Citric Acid Dosage test result of table
| Mirtazapine dosage | Type of solvent | Solvent usage | Citric Acid Dosage | Dissolution phenomena |
| 0.15g | Purified water | 3ml | 0.15g | It cannot be completely dissolved |
| 0.15g | Purified water | 3ml | 0.24g | It cannot be completely dissolved |
| 0.15g | Purified water | 3ml | 0.3g | It cannot be completely dissolved |
| 0.15g | Purified water | 3ml | 0.39g | It is completely dissolved |
| 0.15g | Purified water | 3ml | 0.45g | It is completely dissolved |
Finally preferably go out Citric Acid Dosage by above-mentioned experiment.
Embodiment 1
When preparing Mirtazapine freeze-drying oral disintegrating tablet, dosage of each component is：
Mirtazapine 15g
Citric acid 40g
Hydroxypropyl methylcellulose 6g
Mannitol 15g
Sucralose 0.9g
Morello essence 0.9g
Purified water is settled to 300ml
Preparation method is：
(1) citric acid is dissolved in the water, adds Mirtazapine raw material, stir evenly to form solution, add mannitol,
Hydroxypropyl methylcellulose, Sucralose, morello essence, stir, and are settled to 300ml with water；
(2) medical fluid made from aspiration step (1), injects 300ul in each bubble-cap mold；
(3) mold for being loaded with medical fluid that step (2) obtains is frozen into type in -90 DEG C of environment middling speed；
(4) the quick-frozen molding solid medical fluid for obtaining step (3) is put into freeze dryer, is deposited under -40 DEG C of low temperature environments
It puts 30 minutes, being evacuated to vacuum degree is 15Pa, is kept for 120 minutes, is warming up to -15 DEG C and is kept for 120 minutes, be warming up to 0 DEG C, protects
It holds 120 minutes, is warming up to 10 DEG C, kept for 120 minutes, be warming up to 20 DEG C, kept for 120 minutes, be warming up to 35 DEG C, kept for 80 points
Clock.
(5) outlet, overlay film, punching, printing lot number.
The present embodiment prepares the white oral disintegrating tablet with fragrance, in being disintegrated in 5~10s in 37 DEG C of water.
Embodiment 2
When preparing Mirtazapine freeze-drying oral disintegrating tablet, dosage of each component is：
Mirtazapine 15g
Citric acid 45g
Mannitol 15g
Gelatin 6g
Steviosin 0.9g
Morello essence 0.9g
Purified water is settled to 300ml
Preparation method is：
(1) citric acid is dissolved in the water, adds Mirtazapine raw material, stir evenly to form solution, add mannitol,
Gelatin, Steviosin, morello essence, stir, and are settled to 300ml with water；
(2) medical fluid made from aspiration step (1), injects 300ul in each bubble-cap mold；
(3) mold for being loaded with medical fluid that step (2) obtains is frozen into type in -90 DEG C of environment middling speed；
(4) the quick-frozen molding solid medical fluid for obtaining step (3) is put into freeze dryer, is deposited under -40 DEG C of low temperature environments
It puts 30 minutes, being evacuated to vacuum degree is 15Pa, is kept for 120 minutes, is warming up to -15 DEG C and is kept for 120 minutes, be warming up to 0 DEG C, protects
It holds 120 minutes, is warming up to 10 DEG C, kept for 120 minutes, be warming up to 20 DEG C, kept for 120 minutes, be warming up to 35 DEG C, kept for 80 points
Clock.
(5) outlet, overlay film, punching, printing lot number.
This product is the white oral disintegrating tablet with fragrance, is disintegrated in 10~15s in 37 DEG C of water.
Embodiment 3
When preparing Mirtazapine freeze-drying oral disintegrating tablet, dosage of each component is：
Mirtazapine 15g
Citric acid 40g
Pulullan polysaccharide 15g
Sucralose 0.9g
Morello essence 0.9g
Purified water is settled to 300ml
Preparation method is：
(1) citric acid is dissolved in the water, adds Mirtazapine raw material, stir evenly to form solution, adds Propiram
Polysaccharide, Sucralose, morello essence, stir, and are settled to 300ml with water；
(2) medical fluid made from aspiration step (1), injects 300ul in each bubble-cap mold；
(3) mold for being loaded with medical fluid that step (2) obtains is frozen into type in -90 DEG C of environment middling speed；
(4) the quick-frozen molding solid medical fluid for obtaining step (3) is put into freeze dryer, is deposited under -40 DEG C of low temperature environments
It puts 30 minutes, being evacuated to vacuum degree is 15Pa, is kept for 120 minutes, is warming up to -15 DEG C and is kept for 120 minutes, be warming up to 0 DEG C, protects
It holds 120 minutes, is warming up to 10 DEG C, kept for 120 minutes, be warming up to 20 DEG C, kept for 120 minutes, be warming up to 35 DEG C, kept for 80 points
Clock.
(5) outlet, overlay film, punching, printing lot number.
This product is white with fragrant oral disintegrating tablet, is disintegrated in 10~30s in 37 DEG C of water.
Test example 1
Freeze-drying tablet disintegration time test method：With 70mm × 20mm × 1.0mm glass slide 2, one is bonded with adhesive tape
Glass slide is opened at end, 1cm × 3cm filter paper item is placed in glass slide bonding 1/3 position of end, long end about 3mm is outside glass slide, medicine
Piece is placed on filter paper, closes glass slide, and upper piece glass slide is pressed on tablet naturally, and about 2cm is opened in open end, with dropper in filter paper
Exposing glass slide end and 37 DEG C of distilled water are added dropwise, filter paper soaks, and freeze-drying tablet water suction avalanche, glass slide open end is closed to 2-3mm, depending on
To be disintegrated terminal.Test result is referring to table 2.
2 embodiment of the present invention of table, 1~3 disintegration time test result
| Disintegration time | Appearance | |
| Embodiment 1 | 5-10s is disintegrated completely | White tablets, any surface finish, easy mold release |
| Embodiment 2 | 10-15s is disintegrated completely | White tablets, any surface finish, easy mold release |
| Embodiment 3 | 10-30s is disintegrated completely | White tablets, any surface finish, easy mold release |
Test example 2
It is preferred that the embodiment of the present invention 1 carries out In Vitro Dissolution experiment.
Divide and take sample (product of Mirtazapine commercially available product and embodiment 1 each 24, every 15mg), according to dissolution determination
Method (four general rules of Chinese Pharmacopoeia version in 2015,0,931 second method), with 0.1M hydrochloric acid solution, pH4.0 acetate buffer, pH4.5
Phosphate buffer, pH6.8 phosphate buffer, each 900ml is as dissolution medium (every kind of dissolution medium commercially available product and embodiment
Each 6 of 1 product), it 50 revs/min of revolving speed, operates according to methods, through 5min, 10min, 15min, 20min, 30min, when 45min,
It taking solution appropriate, filters, precision measures subsequent filtrate 5ml, and it sets in 10ml measuring bottle, is diluted to scale with dissolution medium, shakes up, as
Test solution, according to UV-VIS spectrophotometry (four general rules 0401 of Chinese Pharmacopoeia version in 2015), in the maximum of each medium
Absorbance is measured at absorbing wavelength.
Separately take Mirtazapine reference substance appropriate, accurately weighed, adding methanol in right amount makes to be made after dissolving of the dilution of each dissolution medium
Solution in every 1ml containing about 17 μ g is measured in the same method as reference substance solution.
According to said determination as a result, calculating the amount of dissolution by formula and drawing dissolution curve.
Calculation formula：
Dissolution rate %=(Au/As) × (CS × V/L) × 100
Wherein：
Au=sample solution absorbance
As=contrast solution absorbance
The concentration (mg/ml) of CS=contrast solution
V=900ml × 2
L=labelled amount (mg/ piece)
Limit is the 80% of labelled amount, should meet regulation.
Each dissolution curve is referring to Figure 1 to Fig. 4.
Test example 3
It is preferred that the embodiment of the present invention 1 carries out the research of Bioequivalence, tested with commercialized product Remeron
Research, respectively to before the meal, carry out C after the mealmax(blood medicine reaches Cmax), AUC (area under the curve of haemoconcentration) pharmacokinetic indicator
Test, and grade to it, 90% confidence interval is finally calculated, acceptable standard is thought between 80.00-125.00
It is tested equivalent with reference human-body biological.Test result is referring to Fig. 5, Fig. 6 and the following table 3.
The Bioequivalence test result of table 3 embodiment of the present invention 1 and Remeron
Wherein, T is represented by test preparation (embodiment of the present invention 1), and R represents reference preparation (Remeron).
Claims (10)
1. oral disintegrating tablet is lyophilized in a kind of Mirtazapine, which is characterized in that in parts by weight, including 15 parts of Mirtazapines, 5~10 parts of skeleton branch
Support agent, 10~20 parts of freeze drying protectants, 39~45 parts of solubilizer and 1.5~2 parts of corrigents；And the partial size of Mirtazapine is less than or equal to
50um。
2. oral disintegrating tablet is lyophilized in Mirtazapine as described in claim 1, which is characterized in that in parts by weight, including 15 parts of Mirtazapines,
6 parts of skeletal support agent, 15 parts of freeze drying protectants, 40 parts of solubilizer and 1.8 parts of corrigents.
3. oral disintegrating tablet is lyophilized in Mirtazapine as described in claim 1, which is characterized in that the skeletal support agent is selected from gelatin, hydroxyl
One of third methylcellulose, xylitol, trehalose, pulullan polysaccharide or combinations thereof.
4. oral disintegrating tablet is lyophilized in Mirtazapine as claimed in claim 3, which is characterized in that the skeletal support agent is that hydroxypropyl is fine
Tie up element E5.
5. oral disintegrating tablet is lyophilized in Mirtazapine as described in claim 1, which is characterized in that the freeze drying protectant is mannitol or general
Shandong orchid polysaccharide, preferably mannitol.
6. oral disintegrating tablet is lyophilized in Mirtazapine as described in claim 1, which is characterized in that the solubilizer is selected from glacial acetic acid, lemon
Acid or tartaric acid.
7. oral disintegrating tablet is lyophilized in Mirtazapine as claimed in claim 6, which is characterized in that the solubilizer is citric acid.
8. oral disintegrating tablet is lyophilized in Mirtazapine as described in claim 1, which is characterized in that the corrigent is selected from Sucralose, sweet tea
One of chrysanthemum element, essence or combinations thereof, preferably Sucralose and morello essence.
9. the preparation method of Mirtazapine according to claim 1-8 freeze-drying oral disintegrating tablet, which is characterized in that including with
Lower step：
(1) solubilizer of claim 1 parts by weight and Mirtazapine are added in suitable quantity of water and are sufficiently dissolved, add skeletal support
It is sufficiently uniformly dissolved after agent, freeze drying protectant and corrigent, is settled to 300ml with water；
(2) medical fluid made from aspiration step (1) is added into tablet die；
(3) mold for being loaded with medical fluid that step (2) obtains is frozen into type in -75~-120 DEG C of environment middling speed；
(4) the quick-frozen molding solid medical fluid for obtaining step (3) is put into freeze dryer, is kept for 30 minutes, is vacuumized at -40 DEG C
It is 10~20Pa to vacuum degree, is kept for 120 minutes, is warming up to -25~-15 DEG C and is kept for 120 minutes, be warming up to -15~0 DEG C of holding
It 120 minutes, is warming up to 5~10 DEG C and is kept for 120 minutes, be warming up to 20~25 DEG C and kept for 120 minutes, be warming up to 30~35 DEG C of holdings
180 minutes；
(5) outlet, overlay film, punching, printing lot number.
10. Mirtazapine freeze-drying oral disintegrating tablet according to claim 1-8 is preparing the application in antidepressants.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811101902.9A CN108853042B (en) | 2018-09-20 | 2018-09-20 | Mirtazapine freeze-dried orally disintegrating tablet and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811101902.9A CN108853042B (en) | 2018-09-20 | 2018-09-20 | Mirtazapine freeze-dried orally disintegrating tablet and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108853042A true CN108853042A (en) | 2018-11-23 |
| CN108853042B CN108853042B (en) | 2021-03-26 |
Family
ID=64324576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811101902.9A Active CN108853042B (en) | 2018-09-20 | 2018-09-20 | Mirtazapine freeze-dried orally disintegrating tablet and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108853042B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113502322A (en) * | 2021-06-15 | 2021-10-15 | 苏州天隆生物科技有限公司 | PCR freeze-drying reagent and preparation method thereof |
| WO2023063381A1 (en) * | 2021-10-14 | 2023-04-20 | 静岡県公立大学法人 | Powder drug formulation |
| CN116077450A (en) * | 2022-12-24 | 2023-05-09 | 东北农业大学 | Mirtazapine taste masking orally disintegrating tablet, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0431663A1 (en) * | 1989-12-06 | 1991-06-12 | Akzo Nobel N.V. | Stabilized solutions of psychotropic agents |
| CN101129341A (en) * | 2006-08-22 | 2008-02-27 | 上海医药工业研究院 | Intra-oral disintegration compositions and process for producing same |
| CN101433523A (en) * | 2008-12-22 | 2009-05-20 | 浙江大学 | Breviscapine freeze-dry orally disintegrating tablets and preparation method thereof |
-
2018
- 2018-09-20 CN CN201811101902.9A patent/CN108853042B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0431663A1 (en) * | 1989-12-06 | 1991-06-12 | Akzo Nobel N.V. | Stabilized solutions of psychotropic agents |
| CN101129341A (en) * | 2006-08-22 | 2008-02-27 | 上海医药工业研究院 | Intra-oral disintegration compositions and process for producing same |
| CN101433523A (en) * | 2008-12-22 | 2009-05-20 | 浙江大学 | Breviscapine freeze-dry orally disintegrating tablets and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113502322A (en) * | 2021-06-15 | 2021-10-15 | 苏州天隆生物科技有限公司 | PCR freeze-drying reagent and preparation method thereof |
| WO2023063381A1 (en) * | 2021-10-14 | 2023-04-20 | 静岡県公立大学法人 | Powder drug formulation |
| CN116077450A (en) * | 2022-12-24 | 2023-05-09 | 东北农业大学 | Mirtazapine taste masking orally disintegrating tablet, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108853042B (en) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853042A (en) | A kind of Mirtazapine freeze-drying oral disintegrating tablet and its preparation method and application | |
| CN106422045A (en) | Flexible slow-release micro-needle patch and preparation method thereof | |
| CN104042577B (en) | A kind of stable Topiroxostat tablet and preparation method thereof | |
| CN103006661A (en) | Preparation containing lurasidone hydrochloride and preparation method thereof | |
| CN101904825B (en) | Famciclovir dispersible tablet and preparation method thereof | |
| CN104758265B (en) | A kind of ranolazine sustained release tablet medicament composition and preparation method thereof | |
| CN104173312A (en) | Sustained-release tablet containing felodipine and metoprolol salt and preparation method of sustained-release tablet containing felodipine and metoprolol salt | |
| CN106137985B (en) | A kind of stable palmitinic acid 9-hydroxy-risperidone durative action preparation | |
| CN106074423A (en) | Diabecron sustained-release tablet agent and preparation method thereof | |
| CN105343028A (en) | Medicine composition with norfloxacin and method for preparing medicine composition | |
| CN107773550A (en) | A kind of coenzyme Q10 capsule and preparation method thereof | |
| CN106214646B (en) | A kind of silibinin meglumine preparation | |
| CN101023948A (en) | Rimonabant and cyclodextrin inclusion compound of its salt capable of being as medicine, its preparing method and medicine use | |
| CN108186590A (en) | Huperzine slow-release orally disintegrating tablets and preparation method thereof | |
| CN102805751A (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101041076B (en) | Controlled ointment compound stroma and the preparing method | |
| CN109381431B (en) | Huperzine A sustained-release pellet and preparation method thereof | |
| CN104473896A (en) | Rapidly-disintegrating lamivudine tablets and preparation process thereof | |
| CN105616370A (en) | Ranolazine sustained release tablet medicine composition and preparation method thereof | |
| CN104434856A (en) | Gastric floating glipizide controlled release tablet and preparation process thereof | |
| CN102988324A (en) | Preparation for glipizide compression-coated controlled-release tablets | |
| CN115624533B (en) | Nifedipine controlled release tablet, preparation method and application thereof | |
| CN103432092B (en) | A kind of slow releasing preparation of repaglinide | |
| CN102008734A (en) | Inclusion compound of alpha crystal imatinib and preparation method thereof | |
| CN102552358B (en) | Silymarin composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |